Section 29 (New Zealand) in Bahrain

How the section 29 (new zealand) pathway operates in Bahrain.

About Section 29 (New Zealand)

New Zealand's Medsafe pathway for unapproved medicines.

How Section 29 (New Zealand) works in Bahrain

Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.

Patients in Bahrain seeking access under Section 29 (New Zealand) typically follow this flow: a licensed physician in Bahrain issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.

Documents required in Bahrain

  • Physician prescription and clinical-justification letter.
  • Patient identification and consent.
  • Country-specific NPP/personal-import form.
  • Hospital or clinic attestation where required.

Typical timeline

End-to-end 2-6 weeks in most tier 2 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.

Start a request

Start a request under Section 29 (New Zealand) in Bahrain

AI disclosure & medical review. Content on this page is reviewed by Reserve Meds's AI clinical and regulatory review agents. A US-licensed human pharmacist (sourced through Altima Care, a US-licensed specialty wholesaler) reviews every prescription before dispensing. Regulatory posture is AI-summarized and not legal advice; case-specific questions route to retained outside counsel. Last medically reviewed: .
WhatsApp